Navigation Links
China Botanic Exhibits All-Natural Products at the 65th PHARMACHINA Fair

HARBIN, China, May 17, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM") in China, today announced that the Company successfully showcased its all-natural products at the 65th PHARMACHINA fair ("the fair") recently held in Chengdu, China.

China Botanic's Compound Schisandra Tablets and Tianma Series attracted attention from many consumers, distributors and members of the media community, who visited the Company's booth. Compound Schisandra Tablets are clinically proven to regulate the central nervous system, nourish the kidneys, cure insomnia and palpitations, and are widely used as treatment for neurasthenia. Tianma Series is a botanic drug which dispels coldness and provides relief from headaches caused by shortage of blood supply and blood stasis with very few side-effects.

The attendees at the fair were pleased with the Company's all-natural product offering, demonstrations and displays. Management estimates an approximate revenue contribution of $0.6 million in fiscal year 2011 from the business generated at the fair.

"PHARMCHINA is China's largest pharmaceutical fair with attendees from all over the country, providing an excellent platform for information exchange, medical cooperation, and exhibition of our products," said Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic. "We are pleased with the response we received at the fair this year and the growing number of opportunities the fair provides to promote our brand and products, and to attract domestic and international customers. We believe this is an excellent opportunity to enhance the Company's visibility among consumers and in the media community. We will continue to participate in similar events to build long-term brand recognition and expand our market reach."

ABOUT PHARMCHINAPHARMCHINA is the largest exhibition in China's pharmaceutical industry. With a history of over 30 years, the PHARMCHINA fair covers an area of approximately 70,000 square meters and attracts over 2,800 exhibitors and 120,000 visitors. Twice a year, exhibitors and visitors attend PHARMCHINA for new business opportunities in the rapidly developing China's pharmaceutical market, including chemical-based drugs, TCM, bio-pharmaceuticals, OTC medicine, health care products, cosmetics, and healthcare-related technologies and other services. For more information, please visit

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China. All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China. For more information, please visit

Safe Harbor StatementThis press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management's beliefs, assumptions and expectations of the Company's future operations and financial performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to, the Company's ability to manage expansion of its operations effectively, and other factors detailed in the Company's annual report on Form 10-K and other filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.Company Contact:China Botanic Pharmaceutical Inc.Ms. Portia Tan, IR Contact Tel: +86-451-8260-2162Email: CCG Investor Relations:Mr. Mark Collinson, PartnerPhone: +1-310-954-1343 (Los Angeles)Email: Website: www.ccgirasia.comMr. Crocker Coulson, PresidentPhone: +1-646-213-1915 (New York)Email:

SOURCE China Botanic Pharmaceutical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
3. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
4. China Bionanometer Industries Corporation Promotes New Product Beauty Look in China
5. China Biologic Products Announces Second Quarter 2008 Results Conference Call
6. China Medicine Announces Strong Second Quarter 2008 Results
7. China Biologic Products Establishes Governance and Nominating Committee and Compensation Committee
8. China Bio Energy Holdings Group Reports Second Quarter 2008 Financial Results
9. China Sky One Medical, Inc. Develops Nasal Spray for Rheumatic Disease
10. China-Biotics, Inc. Reports First Quarter 2009 Financial Results
11. China Biologic Products Reports Second Quarter 2008 Results
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica Richman and Zachary Apte, ... their initial angel funding process. Now, they are paying it forward to other ... stage investments in the microbiome space. In this, they join other successful ...
(Date:11/24/2015)... , Nov. 24, 2015 /CNW/ - iCo Therapeutics ... today reported financial results for the quarter ended ... expressed in Canadian dollars and presented under International ... United States ," said Andrew Rae ... advancements regarding iCo-008 are not only value enriching ...
(Date:11/24/2015)... 2015 --> ... "Oligonucleotide Synthesis Market by Product & Services (Primer, Probe, ... DNA, RNAi), End-User (Research, Pharmaceutical & Biotech, Diagnostic Labs) ... market is expected to reach USD 1,918.6 Million by ... CAGR of 10.1% during the forecast period. ...
(Date:11/24/2015)... Israel , Nov. 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) ... on December 29, 2015 at 11:00 a.m. Israel ... Electra Tower, 98 Yigal Allon Street, 36 th Floor, ... of Eric Paneth and Izhak Tamir to the ... Rami Skaliter as external directors; , approval of an amendment to ...
Breaking Biology Technology:
(Date:10/27/2015)... NEW YORK , Oct. 27, 2015 ... the major issues of concern for various industry verticals ... This is due to the growing demand for secure ... practices in various ,sectors, such as hacking of bank ... concerns for electronic equipment such as PC,s, laptops, and ...
(Date:10/27/2015)... , Oct. 27, 2015 Synaptics Inc. (NASDAQ: ... announced that Google has adopted the Synaptics ® ... solutions to power its newest flagship smartphones, the Nexus ... --> --> ... to provide strategic collaboration in the joint development of ...
(Date:10/26/2015)... PALO ALTO, Calif. and LAS ... – Nok Nok Labs , an innovator in ... FIDO Alliance , today announced the launch of its ... the first unified platform enabling organizations to use standards-based ... authentication. The Nok Nok S3 Authentication Suite is ideal ...
Breaking Biology News(10 mins):